NASDAQ:CASI - CASI Pharmaceuticals Stock Price, Forecast & News

CASI Pharmaceuticals' stock was trading at $1.63 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, CASI stock has increased by 27.6% and is now trading at $2.08. View which stocks have been mosted impacted by Coronavirus.

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for CASI Pharmaceuticals in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for CASI Pharmaceuticals.

CASI Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Wednesday, May 20th 2020. View our earnings forecast for CASI Pharmaceuticals.

CASI Pharmaceuticals Inc (NASDAQ:CASI) posted its earnings results on Monday, March, 16th. The biotechnology company reported ($0.12) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.11) by $0.01. The biotechnology company had revenue of $1.34 million for the quarter, compared to analyst estimates of $1.16 million. View CASI Pharmaceuticals' earnings history.

1 equities research analysts have issued 12-month price targets for CASI Pharmaceuticals' shares. Their forecasts range from $3.50 to $3.50. On average, they anticipate CASI Pharmaceuticals' stock price to reach $3.50 in the next year. This suggests a possible upside of 68.3% from the stock's current price. View analysts' price targets for CASI Pharmaceuticals.

News headlines about CASI stock have trended somewhat negative recently, according to InfoTrie Sentiment. The research group identifies positive and negative news coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. CASI Pharmaceuticals earned a coverage optimism score of -1.5 on InfoTrie's scale. They also gave news stories about the biotechnology company a news buzz of 2.0 out of 10, meaning that recent news coverage is very unlikely to have an effect on the company's share price in the immediate future. View the latest news aboutCASI Pharmaceuticals.

Some companies that are related to CASI Pharmaceuticals include Sangamo Therapeutics (SGMO), Oyster Point Pharma (OYST), Krystal Biotech (KRYS), Orchard Therapeutics (ORTX), Novavax (NVAX), Osiris Therapeutics (OSIR), AVITA MED LTD/S (AVMXY), Translate Bio (TBIO), Aerie Pharmaceuticals (AERI), AVITA MED LTD/S (RCEL), Passage Bio (PASG), Atara Biotherapeutics (ATRA), GENFIT S A/ADR (GNFT), BAVARIAN NORDIC/S (BVNRY) and Avrobio (AVRO).

Based on aggregate information from My MarketBeat watchlists, some companies that other CASI Pharmaceuticals investors own include Caladrius Biosciences (CLBS), Frontier Communications (FTR), Celsion (CLSN), Catalyst Pharmaceuticals (CPRX), InterDigital Wireless (IDCC), Bank of Hawaii (BOH), Energy Transfer LP Unit (ET), Novavax (NVAX), Progenics Pharmaceuticals (PGNX) and Rigel Pharmaceuticals (RIGL).

CASI Pharmaceuticals trades on the NASDAQ under the ticker symbol "CASI."

CASI Pharmaceuticals' stock is owned by many different retail and institutional investors. Top institutional investors include IDG Accel China Growth Fund III Associates L.P. (8.28%), Wellington Shields & Co. LLC (1.33%), State Street Corp (0.99%), Charles Schwab Investment Management Inc. (0.31%), California Public Employees Retirement System (0.13%) and Vident Investment Advisory LLC (0.07%). Company insiders that own CASI Pharmaceuticals stock include Brian D Coleman and Wei-Wu He. View institutional ownership trends for CASI Pharmaceuticals.

CASI stock was sold by a variety of institutional investors in the last quarter, including California Public Employees Retirement System, and Bank of America Corp DE. View insider buying and selling activity for CASI Pharmaceuticals.

CASI stock was bought by a variety of institutional investors in the last quarter, including IDG Accel China Growth Fund III Associates L.P., Wellington Shields & Co. LLC, State Street Corp, Zebra Capital Management LLC, Charles Schwab Investment Management Inc., Barclays PLC, UBS Group AG, and Vident Investment Advisory LLC. Company insiders that have bought CASI Pharmaceuticals stock in the last two years include Brian D Coleman, and Wei-Wu He. View insider buying and selling activity for CASI Pharmaceuticals.

Shares of CASI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of CASI stock can currently be purchased for approximately $2.08.

CASI Pharmaceuticals has a market capitalization of $205.96 million and generates $4.13 million in revenue each year. The biotechnology company earns $-46,030,000.00 in net income (profit) each year or ($0.42) on an earnings per share basis. CASI Pharmaceuticals employs 124 workers across the globe. View additional information about CASI Pharmaceuticals.

The official website for CASI Pharmaceuticals is http://www.casipharmaceuticals.com/.

CASI Pharmaceuticals' mailing address is 9620 MEDICAL CENTER DR STE 300, ROCKVILLE MD, 20850. The biotechnology company can be reached via phone at 240-864-2600 or via email at [email protected]